Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 3Active not recruiting 2Withdrawn 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Leukemia 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 14fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 9fludarabine 8Cytarabine 8Busulfan 8Azacitidine 8Whole-Body Irradiation 7Methotrexate 7Cyclosporine 6Tacrolimus 5Filgrastim 5Decitabine 5nilotinib 4Mycophenolic Acid 4Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Dasatinib 3Biopsy 3AP 1903 reagent 3venetoclax 2sabatolimab 2ruxolitinib 2merphos 2magrolimab 2ivosidenib 2decitabine and cedazuridine drug combination 2Stem Cell Transplantation 2Specimen Handling 2Sirolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × fedratinib × Myeloid × Clear all
NCT04955938 2024-07-31

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

University of Chicago

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡